Subscribe
When it comes to the political iceberg of drug prices, there is more than meets the eye. Policies that reduce prices but do not lower consumers’ out-of-pocket costs will not address the main challenge facing most Americans.
By pricing options that protect providers from downside risk,health plans can more clearly evaluate different shared savings contracts and expand them to smaller providers.
Disseminating timely and relevant research findings to policy makers is a national priority to inform health policy decisions. Social media is a novel tool to bridge the communication gap.
This supplement showcases the winning papers from the PAN Challenge, which aimed to foster conversations about how to rein in out-of-pocket costs to eliminate barriers between patients and their critical medical treatments.
Findings of this qualitative interview study suggest promise, but also challenges, with regard to using preventive drug lists to help families manage asthma medication costs.
A trial of electronic note–based decision support showed small effects on management of patients with heart disease and diabetes, mostly because it was infrequently used.
Innovations are powering the evolution of patient-centered care, and health plans are at the center of this innovation story.
This article reviews underlying barriers to health care access and discusses how a value-based diabetes care model could improve patient outcomes and reduce long-term costs.
Although team-based care improved cardiovascular disease risk factors, it had a negative financial impact on a primary care practice.
This commentary explains why comparing a launch price with a value-based price from a cost-effectiveness analysis requires further examination.
The prevalence and predictors of hypoglycemia in South Korean patients with type 2 diabetes were evaluated using a nationwide healthcare database.
While care models are being designed to improve outcomes and reduce costs for complex needs patients, there is only modest evidence of their impact and there are a number of barriers to wider adoption of these care models in practice.
A qualitative study of patient and provider perspectives regarding the after-visit summary and the patient portal features of the electronic health record.
Mitigating cost increases through preemptive care and clinical efficacy to reduce the disease burden of clinically at-risk patients.
A review of exemplary VHA-sponsored telemedicine interventions indicates that telemedicine can efficiently address patient healthcare needs.
How peer-to-peer, community support programs can educate and empower patients to become more adherent to treatments, which will improve outcomes and reduce healthcare costs.
Frequent emergency department (ED) users gave similar reasons for using the ED rather than a clinic compared to other patients, including concerns around convenience, access, and quality.
Opioid use incidence and prevalence rates decreased with implementation of an opioid safety initiative, whereas nonsteroidal anti-inflammatory drug rates remained constant. Rates of adverse events were higher among opioid users.
259 Prospect Plains Rd, Bldg H Cranbury, NJ 08512
609-716-7777
© 2025 MJH Life Sciences®
All rights reserved.